Jurriaan Dekkers

Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ.

Circassia Ltd. develops medicines for allergic and auto-immune diseases. The company was founded by Anthony Barrington Kay and Mark Larché on December 29, 1998 and is headquartered in Oxford, the United Kingdom.

The British United Provident Association Ltd. provides healthcare products and services. It offers health, dental and travel insurance, optical and audiology, and care homes. The company was founded on April 3, 1947 and is headquartered in London, the United Kingdom.

Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany.

Part of GSK Plc, Sterling Winthrop, Inc. is a company that specializes in cameras and duplicating machines. The company is based in Rochester, NY. Sterling Winthrop was acquired by GSK Plc from Eastman Kodak Co. on November 03, 1994 for $2,930 million.

Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY.

Part of Novartis AG, Sandoz Ltd. is a British company that develops, produces and markets medicines. The company is based in Camberley, UK and was founded in 1981.

Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA.

Aescap Venture Management BV is an independent venture capital investment firm based in Amsterdam. Aescap was founded in 2005 by Michiel de Haan and Dinko Valerio. Inspired by the name of the Greek god of healthcare, Aesculapiu, the firm's name is an acronym for 'Accelerating European Science Companies and Products.' The firm focuses on developing growth in European firms in the biomedical sector.

Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland.

Part of Lifexx SA, Immodulon Therapeutics Ltd. is a late-stage clinical biotechnology company based in Uxbridge, UK. Immodulon is developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. The British company is developing imm-101, a heat-killed mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumors including those considered to be immunologically “ cold, ” such as pancreatic cancer. Immodulon's imm-101 based immunotherapy complements other cancer therapies, including immune checkpoint inhibitors and chemotherapy. The company is focused on developing safe and effective immunotherapy treatments. The company was founded in 2007 by Charles Akle, John L. Stanford. Gertjan Bartlema has been the CEO of the company since 2022.

Founded in 1998, Kyowa Kirin Ltd. is a British pharmaceutical company that develops, manufactures, and distributes pharmaceutical products. Part of Kirin Holdings Co., Ltd., the company is based in London, UK.

ViiV Healthcare Ltd. manufactures and distributes pharmaceutical products. Its medicine include Triumeq, Tivicay, Selzentry, Celesentri, Epzicom, Kivexa, Ziagen, Trizivir, Combivir, Retrovir AZT, Lexiva, Telzir, Viracept and Rescriptor. The company was founded in 2009 and is headquartered in Brentford, the United Kingdom.

Impatients N.V. operates an online platform for drug innovations. It provides physicians and patients that are excluded from clinical trials access to drugs in development via early access programs. The company was founded by Ronald Brus, SJaak Vink, Govert J. Schouten, Witt Jan, Erdem Yavuz, and René Beukema in 2012 and is headquartered in Amsterdam, the United Kingdom.

Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom.

Part of Alnylam Pharmaceuticals, Inc., Alnylam Germany GmbH is a company that is leading the translation of RNA Interference (RNAi) into a completely innovative class of medicines, which they believe have the potential to transform the lives of patients with genetic and rare diseases. The company is based in Munich, Germany. The CEOs of the company are David Ronald Jones, Hannes Schmeil, Theresa Marie Heggie. The text in the company's description is in German, but it appears to emphasize the importance of clinical trials in developing new medicines and highlights the company's use of RNAi technology to help patients with limited treatment options.

Founded in 2002, Alnylam UK Ltd. is a subsidiary of Alnylam Pharmaceuticals, Inc. that develops biotechnology products. The company is based in Maidenhead, UK.

Amylon Therapeutics BV is a biopharmaceutical company, which engages in the research and development of therapies for the central nervous system. It specializes in ribonucleic acid modulation technology to target rare genetic disorders. The company was founded by Thomas de Vlaam and is headquartered in Leiden, the Netherlands.

Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation.